GCC19CART Demonstrates 30-Fold Higher Objective Response Rate Than U.S. Standard Therapy in Metastatic Colorectal Cancer at ASGCT 2024

ICT (hereinafter referred to as "ICT"), is a company focused on the development of solid tumor treatments.CAR-TClinical-Stage Biotechnology Company for Cell Therapy Products, Leading Therapies for Solid TumorsGCC19CARTThe research abstract was honored to be selected for inclusion.This timeASGCTAnnual Meeting. Local Time5Month8On the afternoon of the day, ICT Chief Technology OfficerVictor LuDr. represented the company at the event and presented in the form of an oral report.GCC19CARTClinical Trials in the United StatesCARAPIA-1The latest progress.GCC19CARTIt is based on the independent research and development of ICT.CoupledCARThe first candidate product developed by the platform technology，Used for the treatment of recurrence/Refractory Metastatic Colorectal Cancer(R/R mCRC)Patient。

ICTParticipation Information 

• Abstract Title:A phase 1 dose escalation study of a novel coupled CAR T cell therapy, GCC19CART, for patients with metastatic colorectal cancer(Phase I Dose-Escalation Study of GCC19CART, a Novel Coupled CAR T-Cell Therapy for Patients with Metastatic Colorectal Cancer)

• Meeting LoopSection：Genetically Modified Immune Cells for AML and Solid Tumors

• Venue:339-342

• Abstract Display Number:141

ICT (hereinafter referred to as "ICT"), is a company focused on the development of solid tumor treatments.CAR-TClinical-Stage Biotechnology Company for Cell Therapy Products, Leading Therapies for Solid TumorsGCC19CARTThe research abstract was honored to be selected for inclusion.This timeASGCTAnnual Meeting. Local Time5Month8In the afternoon, CTO of ICTVictor LuDr. represented the company at the conference and presented in the form of an oral report.GCC19CARTClinical Trials in the United StatesCARAPIA-1The latest progress.

GCC19CART is an autologous CAR-T candidate product specifically designed to target GCC for the treatment of advanced colorectal cancer.A multi-center Phase I dose-escalation clinical trial initiated by researchers in China showed that, according to the Response Evaluation Criteria In Solid Tumors (RECIST 1.1), the objective response rate (ORR) was 15.4% (2/13) in the low-dose group (1x10^6 CAR-T/kg) and 50% (4/8) in the medium-dose group (2x10^6 CAR-T/kg) for GCC19CART.。

In August 2022, GCC19CART initiated a Phase I clinical trial in the United States. This clinical trialConducted in collaboration with several renowned medical centers in the United States, includingDana FArber (Dana-Farber Cancer Institute, Harvard University),UCSF (University of California, San Francisco) Cancer Center,University of Colorado (Cancer Center) and COH (City of Hope Cancer Center).As of November 1, 2023, low-doseThe dosage group (1x10^6 CAR-T/kg) enrolled four patients, who have received reinfusion treatment and completed the evaluation.According to RECIST1.1 criteria, as independently evaluated by a U.S.-based third party, two patients in the low-dose group achieved partial response (PR), with an ORR of 50%.(The resultBetter than the clinical research data in China at the same dose level), the clinical efficacy is much superior to the third-line standard therapy approved by the U.S. FDA (ORR is only 1%-1.6%).. The clinical trial of the low-dose group has been completed,The clinical trial of the medium-dose group (2x10^6 CAR T/kg) is currently underway. As of April 18, 2024, three patients in the medium-dose group have completed the infusion treatment, two patients have completed the evaluation, and one patient has achieved PR.

Preliminary results from the U.S. Phase I clinical trial indicate that GCC19CART demonstrates significant clinical efficacy and favorable safety in recurrent/refractory metastatic colorectal cancer.Combined with clinical research data in China, it can be seen that clinical efficacy is positively correlated with dosage.The trial is still ongoing, Clinical Trial Registration Number:NCT05319314。

AboutASGCT

The 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) was held on local timeMay 7-11, 2024The meeting was held in Baltimore, Maryland, USA. ASGCT, established in 1996, is the largest professional non-profit medical and scientific organization in the global gene and cell therapy field, with over 5,000 members worldwide. The ASGCT Annual Meeting is the largest and most authoritative academic conference in the global gene and cell therapy field.

About ICT

ICT Biotechnology Co., Ltd. isOneA clinical-stage biotechnology company focused on developing CAR-T cell therapy products for solid tumors. ICT's uniqueCoupledCARPlatform technology aims to overcome the key challenges in treating solid tumors, and based on this platform technology,CAR-TThe product has achieved promising clinical outcomes in the treatment of advanced solid tumors, such as colorectal cancer. The company focuses on advanced colorectal cancer.CAR-TCell Therapy ProductsGCC19CARTIn2021Year8Month received the U.S. Food and Drug Administration(FDA)Clinical trial approval, and on2022Year4Month ObtainedFDAGranted Fast Track Designation, currently in U.S. clinical trialsTestCARAPIA-1 is ongoing, Clinical Trial Number: NCT05319314. ICT is also laying out plans for other solid tumors (including prostate cancer, pancreatic cancer, etc.).AbundantCAR-TCandidate Drug Pipeline.

Statement:This article aims to convey industry development information and explore the frontier progress of biopharmaceuticals.The content of the article represents the author's viewpoint and does not represent the position of EBC Pharma, nor does it constitute any value judgment, investment advice, or medical guidance. If necessary, please consult a professional for investment or visit a regular hospital for medical advice.

Dian Dian "Share”、“Like" and "In Progress"，Give me a little charge~